Neuroplastogen Compositions at Non-Psychedelic Doses

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing psychedelic and psychotomimetic drugs require supervised administration and ancillary therapies due to their psychedelic effects, limiting their therapeutic applicability and efficacy, and existing NMDAR antagonists with psychedelic effects are restricted to treatment-resistant conditions.

Innovation Solution

Development of structural analogues of psychedelic compounds that provide neural plasticity without significant psychedelic or psychotomimetic effects, administered at non-psychedelic dosages to induce neural plasticity and treat various diseases and conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If high doses of psychedelic substances are administered to achieve therapeutic effects, then neural plasticity and therapeutic benefit are improved, but psychedelic/psychotomimetic effects and safety risks worsen

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidpsychedelic/psychotomimetic effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by modifying the dosage parameter of psychedelic substances from conventional high doses to low non-psychedelic doses. This parameter change allows the substance to exert neural plasticity effects without producing psychedelic/psychotomimetic effects, thereby resolving the contradiction between therapeutic efficacy and harmful effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a copy of the therapeutic effect (neural plasticity modulation) that is independent of the traditional delivery method (high dose psychedelic experience). By using low doses of the same or related substances, the patent achieves a copy of the therapeutic mechanism without the harmful psychedelic effects, enabling chronic use without the need for controlled settings

Inventive Principle:

Principle #26Copying

2Productivity

If single-session high dose administration is used, then acute therapeutic effects are achieved, but chronic treatment and repeated use are limited

Engineering Contradiction:

Improveacute therapeutic effectVSAvoidchronic treatment capability

Core Design Contradiction:

ProductivityVSDuration of action of stationary object

Solution Approach 1:

The patent enables periodic action through the use of low non-psychedelic doses that can be safely administered repeatedly over time. This allows for chronic treatment protocols where the substance can be given multiple times at intervals, transforming the therapy from a single acute session to a sustainable long-term treatment approach

Inventive Principle:

Principle #19Periodic action

Solution Approach 2:

By changing the dosage parameter from high acute doses to low chronic doses, the patent enables repeated administration without the harmful effects that limit single-session use. This parameter change allows the therapy to extend from one-time intervention to sustained treatment

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If psychedelic substances are administered without specific settings and supervision, then ease of use is improved, but safety and control worsen

Engineering Contradiction:

Improveadministration convenienceVSAvoidsafety and control

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent changes the dosage parameter to non-psychedelic low doses that inherently reduce safety risks. This parameter change allows the substance to be administered without controlled settings and supervision while maintaining safety, thereby improving ease of operation without compromising reliability

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These analogues achieve therapeutic effects comparable to psychedelic drugs but without the need for supervised administration, offering broader applicability and efficacy in treating neurological and psychiatric disorders.

Implementation Method 1

substances providing neural plasticity... modulating neural plasticity and neural receptors like NMDARs

Methodology Applied

Scientific EffectReceptor binding:

Implementation Method 2

modulating neural plasticity and neural receptors

Methodology Applied

Scientific EffectSignal transduction:

Data Source

PatentUS12616706B2Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations

Publication Date: 2026.05.05 ARBORMENTIS LLC

AI summary

Compositions and methods of use comprising serotonin (5-HT) receptor agonists and NMDAR modulating substances, including especially certain substances classified as 5-HT2A agonists presently disclosed to exert NMDAR modulating effects, administered as modulators of neural plasticity, at non-psychedelic/psychotomimetic dosages, posology and formulations, for treatment of diseases and conditions and for improving functions (neuroplastogens).